Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 2
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Efficacy of Mesenchymal Stem Cells With Therapeutic Hypothermia in Infants With Perinatal Hypoxic-Ischemic Encephalopathy (Wharton's jelly-derived MSC)
Hypoxic-Ischemic Encephalopathy, Neonatal · Brain Injuries, Hypoxic-Ischemic
Enrolment: 40 · Results not recorded
Safety and Tolerability of CL2020 (Muse cell product) in Neonatal Hypoxic Ischemic Encephalopathy Patients With Therapeutic Hypothermia, Dose Escalation
Hypoxia-Ischemia, Brain
Enrolment: 9 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57BL/6Intranasal1 x 10 cells per animal (exponent not rendered in the retri…Postnatal day 12, three days after hypoxia-ischaemia; hypothermia given for 4 h…
Model: Neonatal hypoxia-ischaemia induced on postnatal day 9, followed by 4 h of therapeutic hypothermia
Mesenchymal stem cells and hypothermia each improved motor deficits, and only mesenchymal stem cells restored cognitive function. The combination produced worse long-term motor and cognitive deficits and exacerbated brain injury, with enhanced endothelial activation, peripheral immune cell infiltra…
Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.